Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma


Last updated date
Study Location
University of British Columbia
Vancouver, British Columbia, V5Z 1M9, Canada


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaPF-04191834 Single Dose Bronchodilatory Study In Asthma. NCT00723021
  1. Baltimore, Maryland
  2. North Dartmouth, Massachusetts
  3. Kalamazoo, Michigan
  4. Omaha, Nebraska
18 Years+
AsthmaStudy Evaluating Etanercept in Moderate to Severe Asthma NCT00141791
  1. Birmingham, Alabama
  2. Denver, Colorado
  3. Sarasota, Florida
  4. Tallahassee, Florida
  5. Valrico, Florida
  6. Covington, Louisiana
  7. Wheaton, Maryland
  8. Boston, Massachusetts
  9. Rockville Center, New York
  10. Winston-Salem, North Carolina
  11. Portland, Oregon
  12. Richmond, Virginia
  13. Madison, Wisconsin
18 Years+
AsthmaA Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics NCT00150397
  1. Encinitas, California
  2. Riverside, California
  3. DeLand, Florida
  4. Atlanta, Georgia
  5. Normal, Illinois
  6. Madisonville, Kentucky
  7. North Dartmouth, Massachusetts
  8. Springfield, Massachusetts
  9. Minneapolis, Minnesota
  10. Skillman, New Jersey
  11. Cincinnati, Ohio
  12. Lincoln, Rhode Island
  13. Kingsport, Tennessee
  14. Nashville, Tennessee
  15. Dallas, Texas
  16. Madison, Wisconsin
  17. Barrio Aranjuez, San Jose
  18. San Jose,
  19. Mumbai, Maharashtra
  20. Chennai, Tamil Nadu
  21. Vellore, Tamilnadu
  22. Noida, Uttar Pradesh
18 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Official Title  ICMJE Allergen Challenge
Brief Summary Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE Biological: IMA-638 is a biologic
Study Arms  ICMJE 1
Intervention: Biological: IMA-638 is a biologic
Publications * Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1007-14. doi: 10.1164/rccm.201008-1210OC. Epub 2010 Nov 5.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 11, 2006)
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2008
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Inclusion Criteria:

  • generally healthy, men and women with mild allergic asthma, aged 18 to 60 years
  • only asthma med is short-acting bronchodilator used not more than twice weekly
  • FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Exclusion Criteria:

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00410280
Other Study ID Numbers  ICMJE 3174K1-200
B2421001 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP